Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir
Nirmatrelvir (coadministered with ritonavir as $ PAXLOVID^{TM} $) reduces the risk of COVID-19-related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 at high risk of progression to severe disease. Ritonavir is coadministered as a pharmacokinetic enhancer. However, ritonavir may cause drug-drug interactions (DDIs) due to its interactions with various drug-metabolizing enzymes and transporters, including cytochrome P450 (CYP) 3A, CYP2D6, and P-glycoprotein transporters. To better understand the extent of DDIs (or lack thereof) of nirmatrelvir; ritonavir in a clinical setting, this study used real-world evidence (RWE) from the Optum Clinformatics Data Mart database to identify the top 100 drugs most commonly prescribed to US patients at high risk of progression to severe COVID-19 disease. The top 100 drugs were identified based on total counts associated with drugs prescribed to high-risk patients (i.e., ≥ 1 medical condition associated with an increased risk of severe COVID-19) who were continuously enrolled in the database throughout 2019 and had ≥ 1 prescription claim. Each of the 100 drugs was then assessed for DDI risk based on their metabolism, excretion, and transport pathways identified from available US prescribing and medical literature sources. Seventy drugs identified were not expected to have DDIs with nirmatrelvir; ritonavir, including many cardiovascular agents, anti-infectives, antidiabetic agents, and antidepressants. Conversely, 30 drugs, including corticosteroids, narcotic analgesics, anticoagulants, statins, and sedatives/hypnotics, were expected to cause DDIs with nirmatrelvir; ritonavir. This RWE analysis is complementary to the prescribing information and other DDI management tools for guiding healthcare providers in managing DDIs. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
AAPS PharmSci - 25(2023), 5 vom: 20. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gerhart, Jacqueline [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1208/s12248-023-00832-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052308502 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052308502 | ||
| 003 | DE-627 | ||
| 005 | 20231002143957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230720s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12248-023-00832-3 |2 doi | |
| 035 | |a (DE-627)SPR052308502 | ||
| 035 | |a (SPR)s12248-023-00832-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gerhart, Jacqueline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Nirmatrelvir (coadministered with ritonavir as $ PAXLOVID^{TM} $) reduces the risk of COVID-19-related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 at high risk of progression to severe disease. Ritonavir is coadministered as a pharmacokinetic enhancer. However, ritonavir may cause drug-drug interactions (DDIs) due to its interactions with various drug-metabolizing enzymes and transporters, including cytochrome P450 (CYP) 3A, CYP2D6, and P-glycoprotein transporters. To better understand the extent of DDIs (or lack thereof) of nirmatrelvir; ritonavir in a clinical setting, this study used real-world evidence (RWE) from the Optum Clinformatics Data Mart database to identify the top 100 drugs most commonly prescribed to US patients at high risk of progression to severe COVID-19 disease. The top 100 drugs were identified based on total counts associated with drugs prescribed to high-risk patients (i.e., ≥ 1 medical condition associated with an increased risk of severe COVID-19) who were continuously enrolled in the database throughout 2019 and had ≥ 1 prescription claim. Each of the 100 drugs was then assessed for DDI risk based on their metabolism, excretion, and transport pathways identified from available US prescribing and medical literature sources. Seventy drugs identified were not expected to have DDIs with nirmatrelvir; ritonavir, including many cardiovascular agents, anti-infectives, antidiabetic agents, and antidepressants. Conversely, 30 drugs, including corticosteroids, narcotic analgesics, anticoagulants, statins, and sedatives/hypnotics, were expected to cause DDIs with nirmatrelvir; ritonavir. This RWE analysis is complementary to the prescribing information and other DDI management tools for guiding healthcare providers in managing DDIs. Graphical Abstract | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a drug-drug interactions |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a metabolism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a real-world evidence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ritonavir |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Draica, Florin |4 aut | |
| 700 | 1 | |a Benigno, Michael |4 aut | |
| 700 | 1 | |a Atkinson, Jo |4 aut | |
| 700 | 1 | |a Reimbaeva, Maya |4 aut | |
| 700 | 1 | |a Francis, Domenick |4 aut | |
| 700 | 1 | |a Baillon-Plot, Nathalie |4 aut | |
| 700 | 1 | |a Sidhu, Gurinder Singh |4 aut | |
| 700 | 1 | |a Damle, Bharat D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSci |d Arlington, Va. : Soc., 1999 |g 25(2023), 5 vom: 20. Juli |w (DE-627)SPR024632651 |w (DE-600)2045715-7 |x 1522-1059 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:5 |g day:20 |g month:07 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12248-023-00832-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 5 |b 20 |c 07 | ||